Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Chief Financial Officer | March 19, 2024 | March 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date March 19, 2024 · Filed March 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 246,534 |
Reported balance
After 2024-03-19 transaction · row 1
1 source rowRow 1 · 2024-03-19 · Exercise / conversion · Acquired 20,041 · Balance 246,534 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2025-05-19 | Direct | 0 |
Reported balance
After 2024-03-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-19 · Exercise / conversion · Disposed 20,041 · Balance 0 F1: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2018 Filed Sep 19, 2018 16:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 200 | $72.03 | $14,406.00 |
DisclosureSEC source: 0001562180-18-003984 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,522 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $71.55 to $72.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 16:26 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,561 | $70.43 | $109,941.23 |
DisclosureSEC source: 0001562180-18-003984 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,722 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $70.05 to $70.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,301 | $65.99 | $85,852.99 |
DisclosureSEC source: 0001562180-18-003680 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $65.80 to $66.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 6,199 | $65.31 | $404,856.69 |
DisclosureSEC source: 0001562180-18-003680 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,584 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.80 to $65.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,500 | $77.88 | $116,820.00 |
DisclosureSEC source: 0001562180-18-003328 · primarydocument.xml · nonDerivative · entry 4 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,783 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $77.35 to $78.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 862 | $76.60 | $66,029.20 |
DisclosureSEC source: 0001562180-18-003328 · primarydocument.xml · nonDerivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $76.30 to $77.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,510 | $75.18 | $188,701.80 |
DisclosureSEC source: 0001562180-18-003328 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,145 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $74.70 to $75.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,628 | $74.19 | $194,971.32 |
DisclosureSEC source: 0001562180-18-003328 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,655 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $73.65 to $74.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,343 | $56.90 | $247,116.70 |
DisclosureSEC source: 0001562180-18-003059 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $56.70 to $57.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,157 | $56.20 | $177,423.40 |
DisclosureSEC source: 0001562180-18-003059 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,626 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $55.70 to $56.675. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2018 Filed May 16, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,455 | $50.76 | $124,615.80 |
DisclosureSEC source: 0001562180-18-002520 · primarydocument.xml · nonDerivative · entry 3 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,783 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $50.60 to $50.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2018 Filed May 16, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,945 | $49.93 | $196,973.85 |
DisclosureSEC source: 0001562180-18-002520 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,238 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.60 to $50.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2018 Filed May 16, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,100 | $49.21 | $54,131.00 |
DisclosureSEC source: 0001562180-18-002520 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,183 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.60 to $49.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,151 | $37.85 | $81,415.35 |
DisclosureSEC source: 0001562180-18-001904 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $37.70 to $38.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,849 | $37.34 | $106,381.66 |
DisclosureSEC source: 0001562180-18-001904 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,434 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $36.70 to $37.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,000 | $30.00 | $150,000.00 |
DisclosureSEC source: 0001562180-18-001723 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 16:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-18-001565 · primarydocument.xml · derivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,900 Underlying: Common Stock · 60,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 424,900 shares, became exercisable as follows: 284,683 of the shares subject to the option are initial shares ("Initial Shares") and 140,217 of the shares subject to the option are contingent shares ("Contingent Shares"). 72,235 of the Initial Shares vested on September 17, 2014, 53,112 of the Initial Shares vested on September 17, 2015 and an additional 4,426 of the Initial Shares vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. F2 · derivative.exercise_date: (Continued from footnote 1) Notwithstanding the foregoing, 59,533 shares subject to this option that would otherwise vest monthly between January 2018 and September 2018 were deemed vested as of December 31, 2015 on January 28, 2016 due to subsequent events. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 16:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 60,000 | $0.85 | $51,000.00 |
DisclosureSEC source: 0001562180-18-001565 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,000 | $30.00 | $150,000.00 |
DisclosureSEC source: 0001562180-18-001387 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,000 | $30.16 | $150,800.00 |
DisclosureSEC source: 0001562180-18-000340 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 16:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-18-000269 · primarydocument.xml · derivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,900 Underlying: Common Stock · 30,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 424,900 shares, became exercisable as follows: 284,683 of the shares subject to the option are initial shares ("Initial Shares") and 140,217 of the shares subject to the option are contingent shares ("Contingent Shares"). 72,235 of the Initial Shares vested on September 17, 2014, 53,112 of the Initial Shares vested on September 17, 2015 and an additional 4,426 of the Initial Shares vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. F2 · derivative.exercise_date: (Continued from footnote 1) Notwithstanding the foregoing, 59,533 shares subject to this option that would otherwise vest monthly between January 2018 and September 2018 were deemed vested as of December 31, 2015 on January 28, 2016 due to subsequent events. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 16:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 30,000 | $0.85 | $25,500.00 |
DisclosureSEC source: 0001562180-18-000269 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 16:46 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001562180-18-000239 · primarydocument.xml · derivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2019 while the optionee provides continuous service to the Issuer. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,994 | $30.00 | $149,820.00 |
DisclosureSEC source: 0001562180-17-003975 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 16:24 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 6 | $30.00 | $180.00 |
DisclosureSEC source: 0001562180-17-003975 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,277 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,000 | $25.30 | $126,500.00 |
DisclosureSEC source: 0001562180-17-003628 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 16:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,000 | $33.25 | $166,250.00 |
DisclosureSEC source: 0001562180-17-003273 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.95 to $33.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,311 | $27.74 | $64,107.14 |
DisclosureSEC source: 0001562180-17-002982 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $27.55 to $28.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 16:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,689 | $27.08 | $72,818.12 |
DisclosureSEC source: 0001562180-17-002982 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,594 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.55 to $27.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 16:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 835 | $21.43 | $17,894.05 |
DisclosureSEC source: 0001562180-17-002730 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,283 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.40 to $21.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 16:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,205 | $20.96 | $46,216.80 |
DisclosureSEC source: 0001562180-17-002730 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,118 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.40 to $21.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 17, 2017 Filed Jul 19, 2017 16:22 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,100 | $19.81 | $61,411.00 |
DisclosureSEC source: 0001562180-17-002493 · primarydocument.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,323 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $19.70 to $20.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 30, 2017 Filed Jul 19, 2017 16:22 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 911 | $15.73 | $14,325.48 |
DisclosureSEC source: 0001562180-17-002493 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,423 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on January 1, 2017. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 16:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,100 | $18.75 | $58,125.00 |
DisclosureSEC source: 0001562180-17-002297 · primarydocument.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,512 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.45 to $19.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2017 Filed May 17, 2017 17:00 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,100 | $19.07 | $59,117.00 |
DisclosureSEC source: 0000899243-17-013535 · doc4.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,612 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.75 to $19.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 21:00 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 327 | $21.42 | $7,004.34 |
DisclosureSEC source: 0000899243-17-010931 · doc4.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,712 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.40 to $21.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 21:00 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,773 | $20.95 | $58,094.35 |
DisclosureSEC source: 0000899243-17-010931 · doc4.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,039 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.40 to $21.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:00 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0000899243-17-000693 · doc4.xml · derivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2017-01-03 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer. Read SEC document |
| December 31, 2016 Filed Jan 6, 2017 17:00 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 1,372 | $6.79 | $9,317.94 |
DisclosureSEC source: 0000899243-17-000693 · doc4.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,812 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2016 through December 31, 2016. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.